Trial Information

- To determine the role of trastuzumab in the generation of HER2-specific antibodies in
breast cancer patients undergoing adjuvant combination therapy.

- To determine whether the improved disease-free period and overall survival of patients
treated in the adjuvant setting with combination of chemotherapy and trastuzumab is
dependent on the Fcγ receptor genotype of the patient.

Name

Location

We are a Cancer Social Network, Resource Directory & Education Hub supporting all those affected by cancer. knowcancer.com is intended to be solely for informational purposes and should not be a substitute for professional medical advice, diagnosis or treatment.